[Therapeutic goals in hyperlipoproteinemia]

Area of Science:

• Cardiology and Lipidology
• Pharmacology
• Public Health

Context:

• Hyperlipoproteinaemias (HLP) management requires a holistic approach beyond biochemical targets.
• Intervention studies guide HLP treatment goals: reduced mortality, ischemic heart disease (IHD), cerebrovascular accidents (CVA), and improved quality of life.
• Hypolipidaemic agents, especially statins, offer non-lipid benefits alongside lipid spectrum optimization.

Purpose:

• To emphasize patient-centered care in HLP treatment over solely achieving biochemical values.
• To define primary HLP treatment goals based on intervention study outcomes.
• To discuss target lipid values and the role of aggressive treatment for high-risk patients.

Summary:

• HLP treatment prioritizes patient well-being and clinical outcomes like reduced mortality and cardiovascular events.
• Key lipid targets include total cholesterol <5 mmol/l, LDL cholesterol <3 mmol/l, triglycerides <2 mmol/l, and HDL cholesterol >1 mmol/l.
• Aggressive lipid lowering, particularly LDL cholesterol to <2.5 mmol/l, is beneficial for patients with manifest IHD, with statins being the primary therapeutic option.

Impact:

• Shifts focus from biochemical targets to comprehensive patient care and clinical outcomes in HLP.
• Provides evidence-based lipid targets for HLP management, adaptable to individual patient risk.
• Highlights the critical role of statins and lipid optimization in reducing cardiovascular morbidity and mortality.